On Friday, Avidity Biosciences Inc (RNA) stock saw a decline, ending the day at $42.18 which represents a decrease of $-7.79 or -15.59% from the prior close of $49.97. The stock opened at $50.32 and ...

Avidity Biosciences (NASDAQ:RNA) has surged ~16% Wednesday, reaching an all-time high of $56.00 earlier in the trading ...

Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space.

State of New Jersey Common Pension Fund D bought a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Joseph Schwartz has given his Buy rating due to a combination of factors that highlight Avidity Biosciences’ promising developments in precision cardiology. The company recently introduced two new ...

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a ...

2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class ...

Avidity Biosciences Inc. has announced two new precision cardiology development candidates targeting rare genetic cardiomyopathies. AOC-1086 targets phospholamban (PLN) cardiomyopathy and AOC-1072 ...

2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-reports-third-quarter-2024-financial-results-and-recent ...